Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 37, 2022 - Issue 1
Submit an article Journal homepage
2,477
Views
2
CrossRef citations to date
0
Altmetric
Research Papers

Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs

Qiaohua Qina Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, PR ChinaView further author information
,
Ruifeng Wanga Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, PR China;b Department of Pharmacy, Shanxi Medical University, Taiyuan, PR ChinaView further author information
,
Qinglin Fua Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, PR ChinaView further author information
,
Guoqi Zhanga Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, PR ChinaView further author information
,
Tianxiao Wua Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, PR ChinaView further author information
,
Nian Liua Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, PR ChinaView further author information
,
Ruicheng Lva Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, PR ChinaView further author information
,
Wenbo Yina Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, PR ChinaView further author information
,
Yin Suna Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, PR ChinaView further author information
,
Yixiang Suna Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, PR ChinaView further author information
,
Dongmei Zhaoa Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, PR ChinaCorrespondence[email protected]
View further author information
&
Maosheng Chenga Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, PR ChinaView further author information
 show all
Pages 2241-2255 | Received 31 Mar 2022, Accepted 05 Jul 2022, Published online: 17 Aug 2022

References

  • Schaller MD, Borgman CA, Cobb BS, et al. Pp125fak a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci U S A 1992;89:5192–6.
  • Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci 2003;116:1409–16.
  • Golubovskaya VM. Focal adhesion kinase as a cancer therapy target. Anticancer Agents Med Chem 2010;10:735–41.
  • Kessler BE, Sharma V, Zhou Q, et al. Fak expression, not kinase activity, is a key mediator of thyroid tumorigenesis and protumorigenic processes. Mol Cancer Res 2016;14:869–82.
  • Beraud C, Dormoy V, Danilin S, et al. Targeting fak scaffold functions inhibits human renal cell carcinoma growth. Int J Cancer 2015;137:1549–59.
  • Gogate PN, Kurenova EV, Ethirajan M, et al. Targeting the c-terminal focal adhesion kinase scaffold in pancreatic cancer. Cancer Lett 2014;353:281–9.
  • Sood AK, Coffin JE, Schneider GB, et al. Biological significance of focal adhesion kinase in ovarian cancer. Am J Pathol 2004;165:1087–95.
  • Beierle EA, Massoll NA, Hartwich J, et al. Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses. Clin Cancer Res 2008;14:3299–305.
  • Furuyama K, Doi R, Mori T, et al. Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J Surg 2006;30:219–26.
  • van Nimwegen MJ, Verkoeijen S, van Buren L, et al. Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation. Cancer Res 2005;65:4698–706.
  • Zhang J, He DH, Zajac-Kaye M, Hochwald SN. A small molecule fak kinase inhibitor, gsk2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle 2014;13:3143–9.
  • Kurmasheva RT, Gorlick R, Kolb EA, et al. Initial testing of vs-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the pediatric preclinical testing program. Pediatr Blood Cancer 2017;64:e26304.
  • Crompton BD, Carlton AL, Thorner AR, et al. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in ewing sarcoma. Cancer Res 2013;73:2873–83.
  • Schwock J, Dhani N, Hedley DW. Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin Ther Targets 2010;14:77–94.
  • Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov 2017;16:101–14.
  • Churcher I. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones? J Med Chem 2018;61:444–52.
  • Cromm PM, Samarasinghe KTG, Hines J, Crews CM. Addressing kinase-independent functions of FAK via protac-mediated degradation. J Am Chem Soc 2018;140:17019–26.
  • Popow J, Arnhof H, Bader G, et al. Highly selective PTK2 proteolysis targeting chimeras to probe focal adhesion kinase scaffolding functions. J Med Chem 2019;62:2508–20.
  • Gao H, Wu Y, Sun Y, et al. Design, synthesis, and evaluation of highly potent FAK-targeting protacs. ACS Med Chem Lett 2020;11:1855–62.
  • Gao H, Zheng C, Du J, et al. Fak-targeting protac as a chemical tool for the investigation of non-enzymatic FAK function in mice. Protein Cell 2020;11:534–9.
  • Law RP, Nunes J, Chung CW, et al. Discovery and characterisation of highly cooperative FAK-degrading protacs. Angew Chem Int Ed Engl 2021;60:23327–34.
  • Liu J, Xue L, Xu X, et al. FAK-targeting protac demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer. Exp Cell Res 2021;408:112868.
  • Zhou B, Wang GZ, Wen ZS, et al. Somatic mutations and splicing variants of focal adhesion kinase in non-small cell lung cancer. J Natl Cancer Inst 2018;110.
  • Klein VG, Townsend CE, Testa A, et al. Understanding and improving the membrane permeability of vh032-based protacs. ACS Med Chem Lett 2020;11:1732–8.
  • Edmondson SD, Yang B, Fallan C. Proteolysis targeting chimeras (protacs) in ‘beyond rule-of-five’ chemical space: recent progress and future challenges. Bioorg Med Chem Lett 2019;29:1555–64.
  • Maple HJ, Clayden N, Baron A, et al. Developing degraders: principles and perspectives on design and chemical space. Medchemcomm 2019;10:1755–64.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.